Literature DB >> 16056259

The TCL1 family of oncoproteins: co-activators of transformation.

Michael A Teitell1.   

Abstract

The T-cell leukaemia/lymphoma 1 (TCL1)-family oncoproteins augment AKT signal transduction and enhance cell proliferation and survival. Chromosome rearrangements, faulty developmental silencing and Epstein-Barr virus infection appear to dysregulate the expression of TCL1-family genes, provoking several important types of lymphocyte cancer. A key role for TCL1 proteins in cell transformation has been established in studies of transgenic mouse models, which develop a unique spectrum of T- and B-cell malignancies. How TCL1 proteins are regulated and dysregulated, how they promote transformation and the potential for therapies modelled on TCL1 interactions have important implications for understanding and treating lymphocyte cancers.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16056259     DOI： 10.1038/nrc1672

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  46 in total

1.  Expression phenotype changes of EBV-transformed lymphoblastoid cell lines during long-term subculture and its clinical significance.

Authors:  J-E Lee; H-Y Nam; S-M Shim; G-R Bae; B-G Han; J-P Jeon
Journal:  Cell Prolif       Date:  2010-08       Impact factor: 6.831

2.  Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL).

Authors:  Alexey Palamarchuk; Pearlly S Yan; Nicola Zanesi; Linan Wang; Benjamin Rodrigues; Mark Murphy; Veronica Balatti; Arianna Bottoni; Natalya Nazaryan; Hansjuerg Alder; Laura Rassenti; Thomas J Kipps; Michael Freitas; Carlo M Croce; Yuri Pekarsky
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

3.  TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.

Authors:  Jinsheng Weng; Seema Rawal; Fuliang Chu; Hyun Jun Park; Rakesh Sharma; David A Delgado; Luis Fayad; Michelle Fanale; Jorge Romaguera; Amber Luong; Larry W Kwak; Sattva S Neelapu
Journal:  Blood       Date:  2012-05-29       Impact factor: 22.113

Review 4.  Mature T-cell leukemias: Molecular and Clinical Aspects.

Authors:  Nathanael G Bailey; Kojo S J Elenitoba-Johnson
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

5.  EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cells.

Authors:  Francesco Boccellato; Eleni Anastasiadou; Paola Rosato; Bettina Kempkes; Luigi Frati; Alberto Faggioni; Pankaj Trivedi
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

6.  Dysregulated TCL1 requires the germinal center and genome instability for mature B-cell transformation.

Authors:  Rhine R Shen; David O Ferguson; Mathilde Renard; Katrina K Hoyer; Unkyu Kim; Xingpei Hao; Frederick W Alt; Robert G Roeder; Herbert C Morse; Michael A Teitell
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

7.  Interaction between TCL1 and Epac1 in the activation of Akt kinases in plasma membranes and nuclei of 8-CPT-2-O-Me-cAMP-stimulated macrophages.

Authors:  Uma K Misra; Steven J Kaczowka; Salvatore V Pizzo
Journal:  Cell Signal       Date:  2007-10-12       Impact factor: 4.315

8.  ZFX regulates glioma cell proliferation and survival in vitro and in vivo.

Authors:  Zhichuan Zhu; Kui Li; Dafeng Xu; Yongjie Liu; Hailiang Tang; Qing Xie; Liqian Xie; Jiwei Liu; Hongtao Wang; Ye Gong; Zelan Hu; Jing Zheng
Journal:  J Neurooncol       Date:  2013-01-16       Impact factor: 4.130

9.  Versican upregulation in Sézary cells alters growth, motility and resistance to chemotherapy.

Authors:  K Fujii; M B Karpova; K Asagoe; O Georgiev; R Dummer; M Urosevic-Maiwald
Journal:  Leukemia       Date:  2015-04-27       Impact factor: 11.528

10.  Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas.

Authors:  Matthew J Frank; David W Dawson; Steven J Bensinger; Jason S Hong; Wendy M Knosp; Lizhong Xu; Cynthia E Balatoni; Eric L Allen; Rhine R Shen; Dafna Bar-Sagi; Gail R Martin; Michael A Teitell
Journal:  Blood       Date:  2009-01-15       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.